Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05364554 · ClinicalTrials.gov registry record · Phase 2
A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
NCT05364554 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 227 participants.
The verdict
NCT05364554, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis.
Interventions
- DRUG JNJ-77242113
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2023-09-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05364554
The ClinicalTrials.gov registry entry for NCT05364554 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JNJ-77242113 is the first listed.
NCT05364554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05364554 about?
NCT05364554 is a clinical study titled "A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis". The purpose of this study is to evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT05364554?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2022-06-10. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT05364554?
The interventions under investigation include: JNJ-77242113 (DRUG).
Who is sponsoring clinical trial NCT05364554?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.